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aul Mischel took the long way 
around to scientifi  c research. He 
started out as a philosophy student, 
switched to medicine, specializing in 
neuropathology, and then switched again 
to molecular biology research. He now 
keeps a foot in both the clinical and 
research camps, studying the molecular 
biology of glioblastomas—the most 
common malignant brain cancer—in the 
lab and suggesting treatments based on 
those studies in the clinic.
His research includes gene expression 
and mutation profi   ling to identify glio-
blastoma subtypes (1) and analyzing 
commonly disrupted sig-
naling pathways in brain 
cancers (2). As no two 
cancers are identical, the 
ultimate aim is to devise 
tailored therapies for 
patients based on the 
particular defects driving 
their cancer (3). By 
studying tumors with dis-
ruptions in the epidermal 
growth factor receptor 
(EGFR) signaling path-
way, for example, he and 
his colleagues discovered why it is that 
some patients respond well to inhibitors 
of this pathway while others don’t (4).
Mischel, who now runs a laboratory at 
the David Geffen School of Medicine at 
UCLA, is a man who has clearly found 
his niche. He spoke in a recent interview 
of the decisions and infl  uences that shaped 
his career path and that landed him at just 
the right spot.
SEARCHING FOR A PURPOSE
Why did you choose to study philosophy?
The simple answer is that my father was a 
philosophy professor, and I was fascinated 
by him and by what he did. So, when I 
was 18, 19, it seemed to me the most 
meaningful or interesting thing you could 
possibly do—study philosophy and think 
about the mind.
So why the switch to medicine?
My father passed away from stomach 
cancer when I was 14, and it had a pro-
found effect on my life. When I was in my 
late teens, I had a vague notion of wanting 
to use my life to try to do something about 
cancer, but I didn’t really know how. After 
graduating at age 21, however, it really 
kicked in. I thought, “This is my life and 
my chance to do something.”
That decision entailed going back and 
taking all my science courses at night 
school at Harvard. After that, I started 
medical school at Cornell. I was deter-
mined that I’d somehow end up doing 
something for patients with cancer, though 
I was a little unclear as to what that would 
actually be.
But your residency was in neuropathology, 
not oncology. Why was that?
The theme of the mind had also remained 
very central to me. Around the time that I 
was getting ready to graduate, I even con-
sidered becoming a psychiatrist, because 
I thought it would be a great way to link 
the mind and the brain. My father’s brother, 
who continues to have a huge impact on 
my life, is a very famous psychologist, 
Walter Mischel—he’s a member of the 
National Academy of Sciences. I spent a 
lot of time talking to him about my career. 
I still do.
Then I got to witness a brain-cutting 
session—I watched a human brain being 
dissected. I immediately thought, “This 
is important, this is something that I 
want to do.”
You had still not quite found your calling.
No. At the end of the residency, I was 
offered a faculty position at UCLA, but I 
asked to defer because I felt at the time 
that the most interesting thing that I could 
do was to move into molecular biology. I 
had a systems level understanding of the 
brain, an anatomical and pathological 
understanding, but not a molecular under-
standing. And that’s the way the world 
was moving. This was 1996.
I applied to do a postdoc in Louis 
Reichardt’s lab. Having absolutely zero 
background in molecular biology, my fi  rst 
year in Lou’s lab alternated between com-
edy and tragedy. It was often very frus-
trating, but I have a fantastic wife, and she 
said, “Believe in yourself; you can get this 
done.” In addition to being the mother of 
my two daughters, she is also a scientist 
herself—Deborah Kado, here at UCLA. 
I have learned to always listen to her!
Being in Lou’s lab, watching how he 
and the people in his lab operated, how 
they approached problems, was an abso-
lutely transformative experience for me. 
It really turned me into a scientist. I owe a 
great deal to Lou.
I rejoined the faculty at UCLA in 1998 
and started working on some basic signal 
transduction biology in Xenopus oocytes. 
But I also had a clinical role of diagnosing 
brain tumors in patients. There was a dis-
connect between my research life and my 
clinical life. I would be looking at patient 
biopsies and often giving a diagnosis that 
carried a death sentence. I thought to 
myself, “The answers for how to treat 
these patients must be locked inside this 
tissue. We’ve got to get at it.”
Around that time, Charles Sawyers at 
UCLA was pioneering the treatment of 
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leukemia patients using signal transduc-
tion inhibitors. After a series of conversa-
tions with Charles, I realized that being 
able to fi  nd deregulated signal transduc-
tion pathways in our patients was the key 
to successful targeted therapies. That was 
a major turning point in my career, and 
I’ve never looked back.
SETTLED AT LAST
You found your niche. So do you think 
of yourself primarily as a scientist or a 
doctor?
I view myself as both—my being a physi-
cian profoundly infl   uences the kind of 
science that I do. And the kind of science 
that I do profoundly infl  uences the kind of 
physician that I am.
I do very little with regard to the clinic. 
However, I’m constantly surrounded by 
clinical material, analyzing tumors for 
their molecular patterns, particularly their 
signal transduction patterns. And the in-
formation is then used to decide how to 
treat patients. Consequently, I’ve found 
myself becoming more of a doctor than I 
expected. I have patients’ family mem-
bers or other physicians calling me say-
ing, “We have this patient with this and 
that. How might we treat them?”
As an example, a colleague called me 
out of desperation about two years ago and 
said, “Can you look at this biopsy from a 
child with a rare tumor and help us come 
up with something?” Based on our molec-
ular pathway analysis, they treated the 
child who had what should have been a 
lethal tumor. And two years later, the child 
is still doing well, with no recurrence.
What was the molecular signature of 
the tumor and how did you treat it?
Our particular interest has been on the 
EGF receptor/PI3-kinase signaling path-
way. This is often up-regulated in tumors, 
but inhibitors targeted at EGFR fre-
quently don’t work as treatments. We 
showed in a New England Journal of 
Medicine paper that this failure can be 
due to the loss of a downstream tumor 
suppressor, called PTEN. If the tumor 
has lost PTEN activity, the downstream 
pathway stays active even if you target 
the signal at the receptor.
In the case of that child, we were able 
to show that PTEN was intact, suggesting 
he would respond well to an EGFR in-
hibitor. And indeed, he’s doing great.
That must be very gratifying.
Yes. But we’re just at the tip of the iceberg, 
because we need to help a lot more people, 
and these patient-specifi  c treatments need 
to become standard practice in medicine. I 
fi  nd it very exciting that we’re now in an 
era where science can profoundly infl  u-
ence what we can do for patients.
That’s one of the reasons that I’m hon-
ored to be interviewed for Journal of Cell 
Biology. I’ve been saying over and over 
again in meetings that cell biologists are 
going to become increasingly important for 
understanding the molecular circuits that 
drive cancer and for being able to use that 
information to treat patients in the clinic.
FUTURE FORAYS
Is there any hope for patients whose 
tumors have lost PTEN activity?
Yes. We’ve been working very hard to 
understand what are the key downstream 
effectors of EGFR/PI3K. And we’re ask-
ing whether we can develop ways of hit-
ting these effectors. We have pretty strong 
data to indicate that we can, so this might 
now potentially widen the window of 
response from something like 15% of 
patients to over 50% of patients.
EGFR is up-regulated in many types of 
cancer, so is there a reason you focus 
on brain cancers?
There are two reasons. One is my own 
historical narrative—I went from neuro-
pathology to fundamental neuroscience, to 
working on brain tumors. It’s where my 
knowledge base comes from. The second is 
that this is a group of patients that is desper-
ately in need of hope.
Until very recently, 
people would say of 
a patient with a brain 
tumor, “Forget it, 
there’s nothing you 
can do. Forget about 
doing research in 
this area, it’s too 
dreadful of a dis-
ease.” This is partly 
because there’s no 
early detection—by the time a person is 
diagnosed, the cancer is already advanced 
in most cases—and partly because, un-
like other tumors that can potentially be 
surgically removed, brain tumor cells 
often grow through the brain like single 
cell–infi  ltrating soldiers.
Brain cancers are also notoriously non-
responsive to traditional chemotherapies 
and radiation therapies. So fi  nding ways to 
target the pathways is a real hope.
One thing that pleases me immensely 
is that now, at national meetings, brain 
tumors have become a hot topic, because 
the science is becoming tractable at last. 
The pharmaceutical companies are now 
interested in helping move their drugs to 
trials in these patients. This is all good 
news for patients.
All of that said, however, what we’re 
doing in brain tumors is entirely transfer-
able to virtually any kind of cancer. So we’re 
also becoming involved in many collabora-
tive projects outside of the brain.
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